Risk Stratified De-Escalated De-Intensified Treatment for High Risk Prostate Cancer Patients Based on Pathologic Criteria, Genetic Score, and Biologic Imaging.

A clinical trial, NCT06369610, is currently underway to test the effectiveness of risk-based de-escalated hormone therapy with radiation in treating patients with prostate cancer. The trial aims to determine if combining androgen deprivation therapy (ADT) with radiation therapy can effectively treat high-risk prostate cancer. The trial will assess various factors such as recovery of hormonal levels, toxicity, quality of life, impotence, and survival rates. The trial is currently in Phase II and is expected to be completed by April 2027. Additionally, there is information about alternative names for medical procedures and imaging techniques, as well as details about another clinical trial for the treatment of high-risk prostate adenocarcinoma. This trial aims to evaluate different treatment approaches, including ADT, radiation therapy, and the use of abiraterone acetate. The trial is not yet recruiting participants and is expected to be completed by April 2027. The eligibility criteria for participants are outlined, and the study is being conducted in the United States by the Mayo Clinic. [Extracted from the article]